Acute Intermittent Porphyria Market is segmented By Treatment (RNA Interference-based Therapy, Givosiran, Symptomatic Treatment), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned.
Dimensione del Mercato in USD Bn
CAGR6.1%
Periodo di Studio | 2024 - 2031 |
Anno di Base per la Stima | 2023 |
CAGR | 6.1% |
Concentrazione del Mercato | High |
Principali Attori | Alnylam Pharmaceuticals, Recordati Rare Diseases, Mitsubishi Tanabe Pharma, Dicerna Pharmaceuticals, Moderna and Among Others. |
The acute intermittent porphyria market is estimated to be valued at USD 1.43 Billion in 2024 and is expected to reach USD 2.17 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031. The market has been expanding in recent years due to the rising prevalence of acute intermittent porphyria worldwide. Factors such as growing awareness about the condition and its treatment options are supporting the growth of this market.